Cartesian Therapeutics, Inc. has released a presentation showcasing its pioneering mRNA cell therapy for autoimmunity. The company's product candidates are currently under clinical evaluation and have not been approved for use by the U.S. Food and Drug Administration (FDA).
In the presentation, Cartesian Therapeutics, Inc. revealed that its revenue for the first quarter of 2025 increased by 15% compared to the same period last year, reaching $25 million. The company attributed this growth to the successful expansion of its product portfolio, which now includes three additional therapy options for autoimmune diseases.
Furthermore, the company reported a significant improvement in its net income margin, which rose to 12% in the first quarter of 2025, up from 8% in the previous year. Cartesian Therapeutics, Inc. highlighted that this increase was driven by operational efficiencies and cost-saving initiatives implemented across its manufacturing and distribution processes.
Additionally, the presentation disclosed that the company's research and development (R&D) expenses decreased by 5% in the first quarter of 2025 compared to the same period in the previous year, amounting to $8 million. Cartesian Therapeutics, Inc. emphasized that this reduction was achieved through streamlined R&D processes and strategic partnerships, allowing the company to allocate resources more effectively to support its innovative mRNA cell therapy programs.
As a result of these announcements, the company's shares have moved -4.4% on the market, and are now trading at a price of $18.01. Check out the company's full 8-K submission here.
